| B1 |
The time course of the immune response to experimental coronavirus infection of man |
Callow et al. [54]
|
Epidemiology and Infection |
UK |
No |
1990 |
2020 |
77 |
0.3 |
1.3 |
352.2 |
| B2 |
Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson’s disease |
Fazzini et al. [55]
|
Movement Disorders |
US |
No |
1992 |
2020 |
52 |
0.7 |
0.9 |
332.3 |
| B3 |
Virology: Coronaviruses |
No author name available [57]
|
Nature |
Unknown |
No |
1968 |
2020 |
13 |
0 |
0.2 |
304.7 |
| B4 |
Survival characteristics of airborne human coronavirus 229
|
Ijaz et al. [58]
|
Journal of General Virology |
Canada |
Yes |
1985 |
2020 |
81 |
0.5 |
1.4 |
205.7 |
| B5 |
Antibodies to coronaviruses OC43 and 229E in multiple sclerosis patients |
Salmi et al. [59]
|
Neurology |
Finland |
No |
1982 |
2020 |
49 |
0.8 |
0.8 |
192.4 |
| B6 |
The effect of ascorbic acid on infection of chick-embryo ciliated tracheal organ cultures by coronavirus |
Atherton et al. [60]
|
Archives of Virology |
Australia |
No |
1978 |
2020 |
15 |
0.1 |
0.2 |
185.8 |
| B7 |
Medical reviews. Coronaviruses |
Monto [61]
|
Yale Journal of Biology and Medicine |
US |
No |
1974 |
2020 |
31 |
0.4 |
0.5 |
179.4 |
| B8 |
Epidemiology of coronavirus respiratory infections |
Isaacs et al. [62]
|
Archives of Disease in Childhood |
UK |
Yes |
1983 |
2020 |
50 |
0.6 |
0.8 |
177.3 |
| B9 |
Immunofluorescence studies on the pathogenesis of hemagglutinating encephalomyelitis virus infection in pigs after oronasal inoculation |
Andries and Pensaert [63]
|
American Journal of Veterinary Research |
Belgium |
No |
1980 |
2020 |
41 |
0.4 |
0.7 |
173.1 |
| B10 |
Virucidal efficacy of physico-chemical treatments against coronaviruses and parvoviruses of laboratory animals |
Saknimit et al. [64]
|
Jikken dobutsu. Experimental animals |
Japan |
Yes |
1988 |
2020 |
25 |
0.2 |
0.4 |
163.3 |
